1. Home
  2. FGEN

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Founded: 1993 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 33.5M IPO Year: 2014
Target Price: $10.00 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.48 EPS Growth: N/A
52 Week Low/High: $0.18 - $2.40 Next Earning Date: 03-17-2025
Revenue: $29,621,000 Revenue Growth: -36.71%
Revenue Growth (this year): 472.13% Revenue Growth (next year): 7.13%

FGEN Daily Stock ML Predictions

Stock Insider Trading Activity of FibroGen Inc (FGEN)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Wettig Thane FGEN CEO Mar 24 '25 Buy $0.35 145,000 $50,663.00 543,329

Share on Social Networks: